$VYGR News
Last published 1d ago
- 1d agoVYGRStifel 2026 Healthcare Conference - VOYAGER THERAPEUTICS INCEarnings Call TranscriptsAll right. Thanks very much. Happy to be here moderating a fireside chat with Al Sandrock, CEO of Voyager Therapeutics. Obviously, Al has a tremendous amount of experience and wealth of knowledge in the neurology space.
- 6d agoVYGRVoyager Reports Third Quarter 2026 Financial and Operating ResultsGlobeNewswire- VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment - - Neurocrine Biosciences partnered Friedreich’s ataxia gene therapy program expected to enter
- 2w agoVYGRVoyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026GlobeNewswireLEXINGTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced two poster
- 3w agoVYGRVoyager Announces CEO Succession Plan, Appoints Robin Swartz PresidentGlobeNewswire- Robin Swartz, Voyager’s Chief Business and Operating Officer, appointed President, effective immediately; expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as CEO in Q1 2027 - - Dr. Sandrock expected to
- 2mo agoVYGRVoyager to Present at Upcoming Investor ConferencesGlobeNewswireLEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company
- 3mo agoVYGRVoyager Reports Second Quarter 2026 Financial and Operating ResultsGlobeNewswire- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 - - Ended Q2 2026 with cash position of $149 million, runway into 2028 - LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) --
- 4mo agoVYGRVoyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026GlobeNewswire- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to
- 4mo agoVYGRVoyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026GlobeNewswireLEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing
- 5mo agoVYGRVoyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid ConferenceGlobeNewswireLEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that Alfred W.
- 5mo agoVYGRVoyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's DiseaseGlobeNewswire- Dosing of adults with early Alzheimer's disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses an IV-delivered,
- 6mo agoVYGRVoyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026GlobeNewswire- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON, Mass., May 13, 2026
- 6mo agoVYGRVoyager Reports First Quarter 2026 Financial and Operating ResultsGlobeNewswire- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - - Ended Q1 2026 with cash
- 6mo agoVYGRVoyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's DiseaseGlobeNewswire- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs - - Additional data
- 7mo agoVYGRStifel 2026 Virtual CNS ForumVOYAGER THERAPEUTICS INCEarnings Call TranscriptsGreat. Thanks very much. It's my pleasure to be moderating this chat with the CEO of Voyager Therapeutics, Al Sandrock, who I'm sure many folks know well from his current role and famous roles prior. Al, maybe we can get
- 8mo agoVYGRVoyager Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsGlobeNewswire- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2
- 9mo agoVYGRVoyager to Present at Upcoming Investor ConferencesGlobeNewswireLEXINGTON, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company
- 1y agoVYGRTransition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal DementiaGlobeNewswireCAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular
- 1y agoVYGRVoyager Reports Third Quarter 2025 Financial and Operating ResultsGlobeNewswire- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and
- 1y agoVYGRVoyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
- 1y agoVYGRVoyager to Present at Upcoming Investor ConferencesGlobeNewswireLEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company
- 1y agoVYGRVoyager Reports Second Quarter 2025 Financial and Operating ResultsGlobeNewswire- Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer's disease franchise - - 11 partnered
- 1y agoVYGRVoyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE ApproachGlobeNewswire- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager's wholly-owned
- 1y agoVYGRVoyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceGlobeNewswireLEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock,
- 1y agoVYGRVoyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy PublicationGlobeNewswireLEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first
- 1y agoVYGRVoyager Reports First Quarter 2025 Financial and Operating ResultsGlobeNewswire– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – Recent Voyager data on
- 1y agoVYGRVoyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual MeetingGlobeNewswire- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg - - Featured data also include
- 1y agoVYGRVoyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025GlobeNewswire- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data
- 1y agoVYGRVoyager Reports Fourth Quarter and Full Year 2024 Financial and Operating ResultsGlobeNewswire- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in
- 1y agoVYGRVoyager Therapeutics Announces Fourth Quarter 2024 Conference Call and WebcastGlobeNewswireLEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024
- 1y agoVYGRVoyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's DiseaseGlobeNewswire- Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile - - MAD study initiated in patients with early
- 1y agoVYGRVoyager Therapeutics to Present at Multiple Upcoming Investor ConferencesGlobeNewswireLEXINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in
- 1y agoVYGRKirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of InvestorsGlobeNewswireNEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ:VYGR). The investigation
- 1y agoVYGRVoyager Provides Update on SOD1 ALS Gene Therapy ProgramGlobeNewswire- Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash runway into mid-2027 – - All other programs remain on track; IND
- 1y agoVYGRVoyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences ConferenceGlobeNewswireLEXINGTON, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will participate in a fireside
- 1y agoVYGRVoyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer's DiseaseGlobeNewswire- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro gene therapy development candidate nominated leveraging
- 1y agoVYGRVoyager Therapeutics, Inc. (VYGR) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoVYGRVoyager Reports Third Quarter 2024 Financial and Operating ResultsGlobeNewswire- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data establish that an
- 2y agoVYGRVoyager Therapeutics to Present at Multiple Upcoming Investor ConferencesGlobeNewswireLEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in
- 2y agoVYGRVoyager Therapeutics Announces Third Quarter 2024 Conference Call and WebcastGlobeNewswireLEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024
- 2y agoVYGRVoyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate SelectedGlobeNewswireLEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee
- 2y agoNVSVYGRVoyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14GlobeNewswireLEXINGTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Novartis AG (NYSE:NVS) has
- 2y agoVYGRVoyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with a newly
- 2y agoVYGRVoyager Therapeutics to Present at Multiple Upcoming Investor ConferencesGlobeNewswireLEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in
- 2y agoVYGRVoyager Therapeutics, Inc. (VYGR) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoVYGRVoyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company ShowcaseGlobeNewswireLEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in
- 2y agoVYGRVoyager Therapeutics Reports Second Quarter 2024 Financial and Operating ResultsGlobeNewswire- Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer's disease - - Three CNS gene therapy programs on track for INDs in
- 2y agoVYGRVoyager Therapeutics Announces Second Quarter 2024 Conference Call and WebcastGlobeNewswireLEXINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report second quarter 2024
- 2y agoVYGRVoyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLEXINGTON, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Eric
- 2y agoVYGRVoyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLEXINGTON, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Nathan
- 2y agoVYGRVoyager Therapeutics to Present at Multiple Virtual Investor ConferencesGlobeNewswireLEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in